Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2006 2
2007 1
2010 1
2011 6
2012 3
2013 3
2014 1
2015 1
2016 1
2017 2
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient?
Prochazka V, Papajik T, Jarosova M, Indrak K. Prochazka V, et al. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011 Jun;155(2):99-108. doi: 10.5507/bp.2011.015. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011. PMID: 21804618 Review.
Clinical behaviour and overall prognosis are highly variable, ranging from indolent forms with occasional spontaneous remissions to rapidly progressive disease. ...
Clinical behaviour and overall prognosis are highly variable, ranging from indolent forms with occasional spontaneous remissions to r …
Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience.
Vráblová L, Blahutová Š, Čermáková Z, Raida L, Szotkowski T, Hubáček J, Rohoň P, Urbanová R, Indrák K, Papajík T, Kolář M, Faber E. Vráblová L, et al. Transfus Clin Biol. 2019 Nov;26(4):299-303. doi: 10.1016/j.tracli.2018.09.001. Epub 2018 Oct 6. Transfus Clin Biol. 2019. PMID: 30361134
RESULTS: 41 patients with neutropenia and hematologic malignancy (15 females and 26 males aged 22-69 (median 45.5)) were given a median 3.5 GTAs per patient (range: 1-17) containing a median 1.3910(10) granulocyte/GTA (range: 0.65-2.81). ...
RESULTS: 41 patients with neutropenia and hematologic malignancy (15 females and 26 males aged 22-69 (median 45.5)) were given a median 3.5 …
The assessment of aspirin resistance by using light transmission and multiple electrode aggregometry.
Ulehlova J, Slavik L, Krcova V, Hutyra M, Galuszka J, Indrak K. Ulehlova J, et al. Int J Lab Hematol. 2011 Jun;33(3):305-9. doi: 10.1111/j.1751-553X.2010.01286.x. Epub 2011 Jan 11. Int J Lab Hematol. 2011. PMID: 21219589
Depending on the method of assessment and studied patients, the prevalence of ASA resistance is rather heterogeneous, ranging from 5% to 45%. The method most commonly used for assessing platelet function is their aggregation. ...
Depending on the method of assessment and studied patients, the prevalence of ASA resistance is rather heterogeneous, ranging from 5% …
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.
Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R. Hoffmann VS, et al. Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29. Leukemia. 2017. PMID: 27568522
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadelphia chromosome-positive and/or BCR-ABL1+ chronic myeloid leukemia (CML) in 20 predefined countries and regions of Europe. Registration time …
The European Treatment and Outcome Study (EUTOS) population-based registry includes data of all adult patients newly diagnosed with Philadel …
2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation.
Papajík T, Mysliveček M, Urbanová R, Buriánková E, Kapitáňová Z, Procházka V, Turcsányi P, Formánek R, Henzlová L, Flodr P, Jarošová M, Indrák K. Papajík T, et al. Leuk Lymphoma. 2014 Feb;55(2):314-9. doi: 10.3109/10428194.2013.802313. Epub 2013 Jun 14. Leuk Lymphoma. 2014. PMID: 23656196
In all patients, the maximum standardized uptake value (SUV(max)) was calculated. The median SUV(max) was 3.4 (range: 1.5-6.3) and 3.1 (range: 1.2-5.9) in newly diagnosed and relapsed patients, respectively. The median SUV(max) of patients with suspected or confirme …
In all patients, the maximum standardized uptake value (SUV(max)) was calculated. The median SUV(max) was 3.4 (range: 1.5-6.3) and 3. …
Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia - update of single center study.
Raida L, Kuba A, Rusinakova Z, Szotkowska R, Skoumalova I, Faber E, Szotkowski T, Rohon P, Hubacek J, Indrak K, Pikalova Z, Jarosova M, Divoka M, Langova K, Papajik T. Raida L, et al. Neoplasma. 2017;64(5):762-769. doi: 10.4149/neo_2017_515. Neoplasma. 2017. PMID: 28592129
Presented are updated results of allogeneic hematopoietic stem cell transplantations (HSCTs) in 25 adult patients with acute lymphoblastic leukemia (ALL) in complete remission (CR) after a reduced intensity conditioning (RIC) combining fludarabine (150 mg/m2) and melphalan (140 m …
Presented are updated results of allogeneic hematopoietic stem cell transplantations (HSCTs) in 25 adult patients with acute lymphoblastic l …
Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
Voglova J, Muzik J, Faber E, Zackova D, Klamova H, Steinerova K, Michalovicova Z, Demitrovicova L, Cmunt E, Novakova L, Tothova E, Belohlavkova P, Mayer J, Indrak K. Voglova J, et al. Neoplasma. 2011;58(3):256-62. doi: 10.4149/neo_2011_03_256. Neoplasma. 2011. PMID: 21395367
The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214) and 32 months (range 1 - 102), respectively. The observed age-standardized incidence of SM after the start of TKI therapy was 8.95 …
The median intervals from the diagnosis of CML and from the start of TKI therapy to the diagnosis of SM were 58 months (range 2 - 214 …
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
Faber E, Friedecký D, Mičová K, Rožmanová S, Divoká M, Jarošová M, Indrák K, Adam T. Faber E, et al. Ann Hematol. 2012 Jun;91(6):923-9. doi: 10.1007/s00277-011-1394-x. Epub 2012 Jan 11. Ann Hematol. 2012. PMID: 22231281
A total of 1,118 measurements were obtained by ultra-performance liquid chromatography-tandem mass spectrometry assay in patients treated with daily dose of imatinib ranging from 100 to 800 mg. Samples were obtained from 1 to 96 h after drug ingestion. ...
A total of 1,118 measurements were obtained by ultra-performance liquid chromatography-tandem mass spectrometry assay in patients treated wi …
Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression could be an effective approach to patients with acute lymphoblastic leukemia.
Raida L, Rusinakova Z, Szotkowska R, Kuba A, Faber E, Rohon P, Szotkowski T, Hubacek J, Pikalova Z, Jarosova M, Divoka M, Indrak K, Langova K, Skoumalova I, Papajik T. Raida L, et al. Neoplasma. 2015;62(5):805-11. doi: 10.4149/neo_2015_097. Neoplasma. 2015. PMID: 26278139
The immunosuppressive effect of T-cell depletion reducing the risk of graft-versus-host disease (GVHD) and non-relapse mortality was compensated by early initiation of reduction and withdrawal of prophylactic immunosuppression aimed at maintaining effective immunological antileuk …
The immunosuppressive effect of T-cell depletion reducing the risk of graft-versus-host disease (GVHD) and non-relapse mortality was compens …
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Faber E, Nausová J, Jarosová M, Egorin MJ, Holzerová M, Rozmanová S, Maresová I, Divoký V, Indrák K. Faber E, et al. Leuk Lymphoma. 2006 Jun;47(6):1082-90. doi: 10.1080/10428190600565057. Leuk Lymphoma. 2006. PMID: 16840200
In three patients, one-to-three doses per week were sufficient to maintain the cytogenetic response for a mean of 30.6 months (range 29 - 33). Six patients tolerated more frequent dosage of 4 - 5 times a week for a mean of 17.8 months (range 3 - 28). ...
In three patients, one-to-three doses per week were sufficient to maintain the cytogenetic response for a mean of 30.6 months (range …
18 results